Skip to main content
SRXH
NYSE Manufacturing

Two Investors Form 9.9% Group in SRX Global, Target Board Changes

Arie Shkolnikov · Analysis by Wiseek AI
Sentiment info
Positive
Importance info
8
Price
$1.01
Mkt Cap
$20.79M
52W Low
$0.71
52W High
$42.612
52W Position info
42% above low
Off High info
98% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

SRXH sits 42% above its 52-week low of $0.71 on elevated volume (1.9× avg).

Summary

Kevin Egan (7.9%) and Lee Kiewiet (2.0%) formed a 13(d) group holding about 9.9% of SRX Global and intend to push the Board on stockholder value, including possible board composition changes or a sale of the company.


Key Events · Ownership and Investor Activity · SRXH

  • 9.9% Activist Group Formed

    Egan (1,605,070 shares, 7.9%) and Kiewiet (396,204 shares, 2.0%) signed a Group Agreement on November 19, 2026, aggregating 2,001,274 shares, about 9.9% of the 20,265,391 shares outstanding as of August 13, 2026.

  • Board Change and Sale Intent Stated

    The filing says the group will engage the Board on enhancing stockholder value, including potential changes to Board composition, and may propose a sale of the Issuer as a whole or in parts.

  • Real Cash Buying, Not Options

    Egan's stake cost approximately $5,973,314 and Kiewiet's approximately $446,515, both from personal funds. Recent open-market buys ran from $1.7810 on 09/24/2026 down to $0.8071 on 11/09/2026 for Egan and $0.7943-$0.9393 for Kiewiet in November.

  • Kiewiet Locked Up Until Annual Meeting

    The Group Agreement bars Kiewiet from selling any shares before the next annual meeting without Egan's prior consent, and Egan controls group expenses and all public communications.


Analysis · SRXH · Manufacturing

Two passive buyers have become a coordinated block large enough to press for board seats or a sale of the company. Kevin Egan and Lee Kiewiet pooled their stakes into a formal 13(d) group holding 2,001,274 shares, about 9.9% of SRX Global, and said plainly they want to talk to the Board about enhancing stockholder value, including changing who sits on it. The buying is real money, not options: Egan's 1,605,070 shares cost roughly $5.97M and Kiewiet's 396,204 shares about $446,515, and both kept adding in November as the price fell toward $0.80-$0.94 from $1.78 in late September. The Group Agreement also locks Kiewiet in — he cannot sell before the next annual meeting without Egan's consent — so the pressure is one-directional for now.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRXH was trading at $1.01 on NYSE in the Manufacturing sector, with a market capitalization of approximately $20.8M. The 52-week trading range was $0.71 to $42.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRXH - Latest Insights